Detalles de la búsqueda
1.
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
BMC Cancer
; 18(1): 526, 2018 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29728098
2.
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.
Breast Cancer Res
; 17(1): 133, 2015 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26429296
3.
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
Breast Cancer Res Treat
; 154(2): 299-308, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26507191
4.
A study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital.
J Surg Oncol
; 111(2): 203-7, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25288020
5.
Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.
BMC Health Serv Res
; 14: 372, 2014 Sep 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-25190451
6.
The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.
Med J Aust
; 199(3): 205-8, 2013 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23909545
7.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Lancet Oncol
; 11(1): 55-65, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20005174
8.
The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.
Clin Breast Cancer
; 16(5): 372-378, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27105769
9.
Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age.
Adv Ther
; 32(12): 1222-36, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26610382
10.
Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancer.
Clin Breast Cancer
; 14(3): 191-7, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24321102
11.
Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer.
Clin Cancer Res
; 19(14): 4008-16, 2013 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23719261
12.
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
J Natl Cancer Inst
; 105(10): 701-10, 2013 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23641039
13.
Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
J Clin Oncol
; 29(35): 4611-9, 2011 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22067390
14.
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
J Clin Oncol
; 26(25): 4063-71, 2008 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18678838
15.
Accurate assessment of human epidermal growth factor receptor 2.
J Clin Oncol
; 30(14): 1727-8; author reply 1728-9, 2012 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22493424
16.
Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial.
J Hepatol
; 43(4): 630-6, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16024131
17.
A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells.
Clin Immunol
; 106(3): 188-96, 2003 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12706405
Resultados
1 -
17
de 17
1
Próxima >
>>